Objectives: To highlight the role of advanced cosmeceuticals—including growth factors, peptides, and antioxidants—in improving wound healing and reducing post-inflammatory hyperpigmentation (PIH) following laser procedures, particularly in Asian skin.
Introduction: Laser resurfacing procedures create controlled dermal injury to induce rejuvenation, but recovery is critical—especially for Asian skin, which has a higher propensity for PIH. Proper post-laser skincare can minimize complications, enhance healing, and improve patient satisfaction. This presentation examines the use of key cosmeceutical ingredients in each phase of wound healing.
Materials / method: A clinical review of studies evaluating the efficacy of L-ascorbic acid, EGF, bFGF, and signal peptides post-laser was conducted. Special attention was paid to trials involving split-face comparisons and data in Fitzpatrick III–V or Chinese populations. Recovery protocols were mapped according to the biological stages of healing: inflammation, proliferation, and remodeling.
Results: Vitamin C (L-AA) with ferulic acid reduced erythema and PIH when introduced 3–5 days post-laser.
Growth factors (EGF, bFGF) accelerated re-epithelialization and improved healing scores.
Peptides (GHK-Cu, palmitoyl peptides) enhanced texture and barrier function.
A phased topical strategy aligned with the wound healing timeline reduced recovery time and pigmentary side effects, particularly in Asian patients.
Conclusion: Optimizing recovery in laser-treated skin—especially for pigment-prone patients—requires active post-care. Clinical evidence supports the use of select cosmeceuticals to enhance healing and reduce complications. Dermatologists should implement phase-specific skincare protocols to support post-procedure outcomes and improve patient experience.
Declaraciones
¿Ha recibido algún tipo de financiamiento para realizar su investigación sobre esta temática?
No
¿Ha recibido algún pago, honorario u otra compensación por su trabajo acerca de esta investigación?
No
¿Tiene vínculos financieros con alguna entidad que podría llegar a competir estrechamente con los medicamentos, materiales o instrumentos tratados en su investigación?
No
¿Posee o ha solicitado una patente relacionada a los materiales, productos o instrumentos utilizados en su investigación?
No
Este trabajo no cuenta con el apoyo de ningún financiamiento directo o indirecto. El autor asume plena responsabilidad sobre el mismo.